Safety being seen in first 3 patients in stem cell therapy clinical trial
Reasonable safety is being seen in a first group of Parkinson’s disease patients who finished dosing in a Phase 1/2a clinical trial of ANPD001, Aspen Neurosciences’ investigational stem cell therapy aiming to replace the nerve